KR20230019424A - 암을 치료하기 위한 조성물 및 방법 - Google Patents

암을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230019424A
KR20230019424A KR1020227040872A KR20227040872A KR20230019424A KR 20230019424 A KR20230019424 A KR 20230019424A KR 1020227040872 A KR1020227040872 A KR 1020227040872A KR 20227040872 A KR20227040872 A KR 20227040872A KR 20230019424 A KR20230019424 A KR 20230019424A
Authority
KR
South Korea
Prior art keywords
ser
domain
cancer
cells
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227040872A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 체리쉬
사라 베이스
스테판 맥콜맥
크리스토프 레이더
히로미 웨스턴
Original Assignee
알파 베타 홀딩스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알파 베타 홀딩스, 엘엘씨 filed Critical 알파 베타 홀딩스, 엘엘씨
Publication of KR20230019424A publication Critical patent/KR20230019424A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227040872A 2020-04-23 2021-04-23 암을 치료하기 위한 조성물 및 방법 Pending KR20230019424A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014550P 2020-04-23 2020-04-23
US63/014,550 2020-04-23
PCT/US2021/028775 WO2021216956A1 (en) 2020-04-23 2021-04-23 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
KR20230019424A true KR20230019424A (ko) 2023-02-08

Family

ID=78270118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227040872A Pending KR20230019424A (ko) 2020-04-23 2021-04-23 암을 치료하기 위한 조성물 및 방법

Country Status (12)

Country Link
US (1) US20230140868A1 (https=)
EP (1) EP4110822A4 (https=)
JP (1) JP7817948B2 (https=)
KR (1) KR20230019424A (https=)
CN (1) CN115485301A (https=)
AU (1) AU2021261003A1 (https=)
BR (1) BR112022019939A2 (https=)
CA (1) CA3172092A1 (https=)
IL (1) IL296576A (https=)
MX (1) MX2022013207A (https=)
PH (1) PH12022553129A1 (https=)
WO (1) WO2021216956A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020145669A1 (ko) 2019-01-10 2020-07-16 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
KR102423686B1 (ko) * 2019-01-10 2022-07-21 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
CN118284622A (zh) * 2021-09-30 2024-07-02 阿尔法贝塔控股有限责任公司 治疗癌症的组合物和方法
CN118542937A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 抗αvβ3抗体和抗PD-1抗体的联合药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0968290B1 (en) * 1997-03-12 2004-12-15 SmithKline Beecham Corporation Anti-alphavbeta3 humanized monoclonal antibodies
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
KR100983997B1 (ko) * 2001-01-09 2010-09-28 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
HUE038848T2 (hu) * 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
BR122020002986A8 (pt) * 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
US10150800B2 (en) * 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
EP3113796A1 (en) * 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2017053423A1 (en) * 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use
MX2019011717A (es) * 2017-03-31 2019-12-16 Univ California Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
CN119367532A (zh) * 2019-08-02 2025-01-28 加利福尼亚大学董事会 用于靶向和杀死α-vβ-3（αvβ3）阳性癌症干细胞（CSC）以及治疗耐药性和转移性癌症的组合物和方法

Also Published As

Publication number Publication date
WO2021216956A1 (en) 2021-10-28
US20230140868A1 (en) 2023-05-11
JP2023523016A (ja) 2023-06-01
CA3172092A1 (en) 2021-10-28
MX2022013207A (es) 2023-01-24
AU2021261003A1 (en) 2022-10-20
PH12022553129A1 (en) 2024-02-26
JP7817948B2 (ja) 2026-02-19
EP4110822A4 (en) 2024-04-10
IL296576A (en) 2022-11-01
EP4110822A1 (en) 2023-01-04
BR112022019939A2 (pt) 2022-12-13
CN115485301A (zh) 2022-12-16

Similar Documents

Publication Publication Date Title
US10487150B2 (en) SIRP alpha-antibody fusion proteins
EP3778641B1 (en) Bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
KR20230019424A (ko) 암을 치료하기 위한 조성물 및 방법
KR20200067833A (ko) 항-sirp-알파 항체 및 관련 방법
TW201011045A (en) Anti-CD5 antibodies
MD3535298T2 (ro) Anticorpi ai PD-1 și utilizări ale acestora
CN110545844A (zh) 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
AU2015350075A1 (en) Methods for tumor treatment using CD3xCD20 bispecific antibody
EP4141033A1 (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
WO2022188832A1 (zh) 含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途
JP2024515396A (ja) 抗ｃｄ４７モノクローナル抗体及びその使用
KR20250035543A (ko) 항-cldn18.2 항체를 포함하는 이중특이적 항체 및 이의 약제학적 조성물 및 이의 용도
EP3915641A1 (en) Anti-cd5 antibodies and methods of use thereof
TW202305005A (zh) 抗ｓｉｇｌｅｃ組合物及其用途
WO2023056326A1 (en) Compositions and methods for treating cancer
US12077597B2 (en) Anti-CD5 antibodies and methods of use thereof
TWI917473B (zh) Bcma/taci抗原結合分子
WO2024040150A1 (en) Binding agents targeting gd2 and their use for treating cancer
WO2025151576A1 (en) Compositions and methods for treating cancer and fibrotic disorders
HK40101629A (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
CA2957531C (en) Sirp alpha-antibody fusion proteins
HK40081163A (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
HK40045394B (en) Bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
HK40120378A (zh) 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
HK40034502B (en) Methods for tumor treatment using cd3xcd20 bispecific antibody

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application